MerLion Pharmaceuticals Pte. Ltd., drug discovery and development company, engages in the research and development of natural products. It operates through two business units, MerLion Research and MerLion Development. The MerLion Research unit is a contract services business, which provides access to natural product collections by offering sample/extract supply services, extract profiling and standardization, assay development, throughput screening, compound purification and structural identification, biocatalyst isolation, and strain improvement. The MerLion Development unit is progressing finafloxacin, a differentiated antibacterial candidate through phase II clinical trials, which is targeted initially for the eradication of Helicobacter pylori and treatment of urinary tract infections. It also provides portfolio of earlier-stage, preclinical antibacterial, and oncology programmes. The company serves pharmaceutical, industrial biotechnology, agro science, food and flavorings, cosmetics, and personal healthcare companies. MerLion Pharmaceuticals Pte. Ltd. was founded in 2002 and is based in Singapore, Singapore with clinical development operations in Berlin, Germany.